{"ID": "DDI-DrugBank.d765.s0.p0", "TEXT1": "CYP3A4 Inhibitors: @DRUG$, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of @DRUG$ when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).", "LBL": "DDI-mechanism", "DRUGA": ["Ketoconazole", "drug", "19-30"], "DRUGB": ["tolterodine", "drug", "135-145"]}
{"ID": "DDI-DrugBank.d765.s1.p0", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["azole antifungals", "group", "84-100"]}
{"ID": "DDI-DrugBank.d765.s1.p1", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["itraconazole", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d765.s1.p2", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p3", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p4", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p5", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p6", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p7", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p8", "TEXT1": "For patients receiving @DRUG$ or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p9", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["itraconazole", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d765.s1.p10", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p11", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p12", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p13", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p14", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p15", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p16", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other @DRUG$ (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p17", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p18", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p19", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d775.s10.p1", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as MIVACRON include certain @DRUG$ (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "DDI-int", "DRUGA": ["nondepolarizing agents", "drug", "67-88"], "DRUGB": ["antibiotics", "group", "123-133"]}
{"ID": "DDI-DrugBank.d765.s1.p21", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p22", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p23", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, @DRUG$, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p24", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d591.s3.p0", "TEXT1": "Thus strong inhibitors of cytochrome P4501A2, such as @DRUG$, given concomitantly during administration of @DRUG$, can interact with Ropivacaine leading to increased ropivacaine plasma levels.", "LBL": "DDI-int", "DRUGA": ["fluvoxamine", "drug", "54-64"], "DRUGB": ["Ropivacaine", "drug", "112-122"]}
{"ID": "DDI-DrugBank.d765.s1.p26", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p27", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p28", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p29", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, @DRUG$) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p30", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p31", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p32", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p33", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p34", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or @DRUG$ (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p35", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, @DRUG$) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p36", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p37", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p38", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, @DRUG$, clarithromycin) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p39", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or @DRUG$ or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p40", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p41", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, @DRUG$) or cyclosporine or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p42", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or @DRUG$, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "196-207"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p43", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or @DRUG$ or vinblastine, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["cyclosporine", "drug", "196-207"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p44", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or @DRUG$, the recommended dose of @DRUG$ is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["vinblastine", "drug", "212-222"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d670.s0.p0", "TEXT1": "Potential for @DRUG$    to Affect Other Drugs @DRUG$ is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.", "LBL": "0", "DRUGA": ["INVEGA", "brand", "14-19"], "DRUGB": ["Paliperidone", "drug", "46-57"]}
{"ID": "DDI-DrugBank.d670.s6.p0", "TEXT1": "Given the primary CNS effects of @DRUG$, @DRUG$    should be used with caution in combination with other centrally acting drugs and alcohol.", "LBL": "0", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["INVEGA", "brand", "47-52"]}
{"ID": "DDI-DrugBank.d670.s6.p1", "TEXT1": "Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other @DRUG$ and alcohol.", "LBL": "DDI-advise", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["centrally acting drugs", "group", "111-132"]}
{"ID": "DDI-DrugBank.d670.s6.p2", "TEXT1": "Given the primary CNS effects of @DRUG$, INVEGA    should be used with caution in combination with other centrally acting drugs and @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s6.p3", "TEXT1": "Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other @DRUG$ and alcohol.", "LBL": "DDI-advise", "DRUGA": ["INVEGA", "brand", "47-52"], "DRUGB": ["centrally acting drugs", "group", "111-132"]}
{"ID": "DDI-DrugBank.d670.s6.p4", "TEXT1": "Given the primary CNS effects of paliperidone, @DRUG$    should be used with caution in combination with other centrally acting drugs and @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["INVEGA", "brand", "47-52"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s6.p5", "TEXT1": "Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["centrally acting drugs", "group", "111-132"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s7.p0", "TEXT1": "@DRUG$ may antagonize the effect of @DRUG$ and other dopamine agonists.", "LBL": "DDI-effect", "DRUGA": ["Paliperidone", "drug", "0-11"], "DRUGB": ["levodopa", "drug", "42-49"]}
{"ID": "DDI-DrugBank.d670.s7.p1", "TEXT1": "@DRUG$ may antagonize the effect of levodopa and other @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Paliperidone", "drug", "0-11"], "DRUGB": ["dopamine agonists", "group", "61-77"]}
{"ID": "DDI-DrugBank.d670.s7.p2", "TEXT1": "Paliperidone may antagonize the effect of @DRUG$ and other @DRUG$.", "LBL": "0", "DRUGA": ["levodopa", "drug", "42-49"], "DRUGB": ["dopamine agonists", "group", "61-77"]}
{"ID": "DDI-DrugBank.d670.s9.p0", "TEXT1": "Potential for Other Drugs to Affect @DRUG$    @DRUG$ is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.", "LBL": "0", "DRUGA": ["INVEGA", "brand", "36-41"], "DRUGB": ["Paliperidone", "drug", "46-57"]}
{"ID": "DDI-DrugBank.d784.s0.p0", "TEXT1": "The concomitant use of @DRUG$ with other @DRUG$ or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.", "LBL": "DDI-effect", "DRUGA": ["oxybutynin", "drug", "23-32"], "DRUGB": ["anticholinergic drugs", "group", "45-65"]}
{"ID": "DDI-DrugBank.d784.s3.p0", "TEXT1": "Mean @DRUG$ plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with ketoconazole, a potent CYP3A4 inhibitor.", "LBL": "0", "DRUGA": ["oxybutynin chloride", "drug", "5-23"], "DRUGB": ["DITROPAN XL", "brand", "85-95"]}
{"ID": "DDI-DrugBank.d784.s3.p1", "TEXT1": "Mean @DRUG$ plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with @DRUG$, a potent CYP3A4 inhibitor.", "LBL": "0", "DRUGA": ["oxybutynin chloride", "drug", "5-23"], "DRUGB": ["ketoconazole", "drug", "119-130"]}
{"ID": "DDI-DrugBank.d784.s3.p2", "TEXT1": "Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when @DRUG$ was administered with @DRUG$, a potent CYP3A4 inhibitor.", "LBL": "DDI-mechanism", "DRUGA": ["DITROPAN XL", "brand", "85-95"], "DRUGB": ["ketoconazole", "drug", "119-130"]}
{"ID": "DDI-DrugBank.d784.s4.p0", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["itraconazole", "drug", "93-104"]}
{"ID": "DDI-DrugBank.d784.s4.p1", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["miconazole", "drug", "110-119"]}
{"ID": "DDI-DrugBank.d784.s4.p2", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p3", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p4", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p5", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as @DRUG$ (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p6", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["miconazole", "drug", "110-119"]}
{"ID": "DDI-DrugBank.d784.s4.p7", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p8", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p9", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p10", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., @DRUG$ and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p11", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p12", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p13", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p14", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and @DRUG$) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p15", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., @DRUG$ and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p16", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p17", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or @DRUG$ (e.g., erythromycin and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p18", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and @DRUG$), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "154-165"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p19", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., @DRUG$ and clarithromycin), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["erythromycin", "drug", "154-165"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p20", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and @DRUG$), may alter @DRUG$ mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["clarithromycin", "drug", "171-184"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s7.p0", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["antacid", "group", "42-48"]}
{"ID": "DDI-DrugBank.d784.s7.p1", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["aluminum hydroxide", "drug", "61-78"]}
{"ID": "DDI-DrugBank.d784.s7.p2", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p3", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p4", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p5", "TEXT1": "Concurrent ingestion of @DRUG$ (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p6", "TEXT1": "Concurrent ingestion of antacid (20 mL of @DRUG$ containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["aluminum hydroxide", "drug", "61-78"]}
{"ID": "DDI-DrugBank.d784.s7.p7", "TEXT1": "Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p8", "TEXT1": "Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p9", "TEXT1": "Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p10", "TEXT1": "Concurrent ingestion of antacid (20 mL of @DRUG$ containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p11", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p12", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p13", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p14", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing @DRUG$, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p15", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and @DRUG$) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p16", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p17", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, @DRUG$, and simethicone) did not significantly affect the exposure of oxybutynin or @DRUG$.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p18", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of @DRUG$ or desethyloxybutynin.", "LBL": "0", "DRUGA": ["simethicone", "drug", "106-116"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p19", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and @DRUG$) did not significantly affect the exposure of oxybutynin or @DRUG$.", "LBL": "0", "DRUGA": ["simethicone", "drug", "106-116"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p20", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["oxybutynin", "drug", "164-173"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d717.s0.p0", "TEXT1": "@DRUG$ has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.", "LBL": "DDI-mechanism", "DRUGA": ["Mitotane", "drug", "0-7"], "DRUGB": ["warfarin", "drug", "59-66"]}
{"ID": "DDI-DrugBank.d717.s0.p1", "TEXT1": "@DRUG$ has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.", "LBL": "0", "DRUGA": ["Mitotane", "drug", "0-7"], "DRUGB": ["warfarin", "drug", "175-182"]}
{"ID": "DDI-DrugBank.d717.s0.p2", "TEXT1": "Mitotane has been reported to accelerate the metabolism of @DRUG$ by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for @DRUG$.", "LBL": "0", "DRUGA": ["warfarin", "drug", "59-66"], "DRUGB": ["warfarin", "drug", "175-182"]}
{"ID": "DDI-DrugBank.d717.s1.p0", "TEXT1": "Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering @DRUG$ to patients on coumarin-type anticoagulants.", "LBL": "0", "DRUGA": ["anticoagulant", "group", "70-82"], "DRUGB": ["Mitotane", "drug", "123-130"]}
{"ID": "DDI-DrugBank.d717.s1.p1", "TEXT1": "Therefore, physicians should closely monitor patients for a change in @DRUG$ dosage requirements when administering Mitotane to patients on @DRUG$.", "LBL": "0", "DRUGA": ["anticoagulant", "group", "70-82"], "DRUGB": ["coumarin-type anticoagulants", "group", "147-174"]}
{"ID": "DDI-DrugBank.d717.s1.p2", "TEXT1": "Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering @DRUG$ to patients on @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["Mitotane", "drug", "123-130"], "DRUGB": ["coumarin-type anticoagulants", "group", "147-174"]}
{"ID": "DDI-DrugBank.d669.s0.p0", "TEXT1": "Concomitant administration of @DRUG$ and @DRUG$ has been associated with erythema and histamine-like flushing and anaphylactoid reactions.", "LBL": "DDI-effect", "DRUGA": ["vancomycin", "drug", "30-39"], "DRUGB": ["anesthetic agents", "group", "45-61"]}
{"ID": "DDI-DrugBank.d669.s1.p0", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["aminoglycosides", "group", "135-149"]}
{"ID": "DDI-DrugBank.d669.s1.p1", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["bacitracin", "drug", "152-161"]}
{"ID": "DDI-DrugBank.d669.s1.p2", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p3", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p4", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p5", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as @DRUG$, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p6", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, @DRUG$, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["bacitracin", "drug", "152-161"]}
{"ID": "DDI-DrugBank.d669.s1.p7", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p8", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p9", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p10", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, @DRUG$, bacitracin, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p11", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, @DRUG$, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p12", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p13", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p14", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, @DRUG$, polymyxin B, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p15", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, @DRUG$, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p16", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, @DRUG$, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p17", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, @DRUG$, colistin, viomycin, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p18", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, @DRUG$, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["colistin", "drug", "177-184"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p19", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, @DRUG$, viomycin, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["colistin", "drug", "177-184"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p20", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, @DRUG$, or @DRUG$, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["viomycin", "drug", "187-194"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d590.s0.p0", "TEXT1": "Coadministration of @DRUG$ with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).", "LBL": "DDI-mechanism", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["clarithromycin", "drug", "32-45"]}
{"ID": "DDI-DrugBank.d590.s0.p1", "TEXT1": "Coadministration of @DRUG$ with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).", "LBL": "0", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["ranitidine", "drug", "76-85"]}
{"ID": "DDI-DrugBank.d590.s0.p2", "TEXT1": "Coadministration of @DRUG$ with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).", "LBL": "0", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s0.p3", "TEXT1": "Coadministration of TRITEC with @DRUG$ resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "32-45"], "DRUGB": ["ranitidine", "drug", "76-85"]}
{"ID": "DDI-DrugBank.d590.s0.p4", "TEXT1": "Coadministration of TRITEC with @DRUG$ resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "32-45"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s0.p5", "TEXT1": "Coadministration of TRITEC with clarithromycin resulted in increased plasma @DRUG$ concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased @DRUG$ plasma concentrations (31%).", "LBL": "0", "DRUGA": ["ranitidine", "drug", "76-85"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s1.p0", "TEXT1": "Coadministration with @DRUG$ results in a slight decrease in the rate of @DRUG$ absorption that is clinically unimportant.", "LBL": "0", "DRUGA": ["aspirin", "brand", "22-28"], "DRUGB": ["salicylate", "group", "74-83"]}
{"ID": "DDI-DrugBank.d590.s2.p0", "TEXT1": "Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from TRITEC.", "LBL": "DDI-mechanism", "DRUGA": ["antacid", "group", "37-43"], "DRUGB": ["ranitidine", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d590.s2.p1", "TEXT1": "Coadministration with a high dose of @DRUG$ (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["antacid", "group", "37-43"], "DRUGB": ["TRITEC", "brand", "175-180"]}
{"ID": "DDI-DrugBank.d590.s2.p2", "TEXT1": "Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of @DRUG$ and may decrease plasma concentrations of bismuth from @DRUG$.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "109-118"], "DRUGB": ["TRITEC", "brand", "175-180"]}
{"ID": "DDI-DrugBank.d590.s4.p0", "TEXT1": "For information on drug interactions associated with @DRUG$, refer to the @DRUG$     package insert.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "53-62"], "DRUGB": ["ZANTAC", "brand", "78-83"]}
{"ID": "DDI-DrugBank.d702.s1.p0", "TEXT1": "These include @DRUG$, @DRUG$, and oral and inhaled steroids.", "LBL": "0", "DRUGA": ["sympathomimetic bronchodilators", "group", "14-44"], "DRUGB": ["methylxanthines", "group", "47-61"]}
{"ID": "DDI-DrugBank.d702.s1.p1", "TEXT1": "These include @DRUG$, methylxanthines, and oral and inhaled @DRUG$.", "LBL": "0", "DRUGA": ["sympathomimetic bronchodilators", "group", "14-44"], "DRUGB": ["steroids", "group", "85-92"]}
{"ID": "DDI-DrugBank.d702.s1.p2", "TEXT1": "These include sympathomimetic bronchodilators, @DRUG$, and oral and inhaled @DRUG$.", "LBL": "0", "DRUGA": ["methylxanthines", "group", "47-61"], "DRUGB": ["steroids", "group", "85-92"]}
{"ID": "DDI-DrugBank.d702.s2.p0", "TEXT1": "However, the co   administration of @DRUG$ with other @DRUG$   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "LBL": "DDI-advise", "DRUGA": ["SPIRIVA", "brand", "36-42"], "DRUGB": ["anticholinergic", "group", "55-69"]}
{"ID": "DDI-DrugBank.d702.s2.p1", "TEXT1": "However, the co   administration of @DRUG$ with other anticholinergic   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.", "LBL": "DDI-advise", "DRUGA": ["SPIRIVA", "brand", "36-42"], "DRUGB": ["ipratropium", "drug", "97-107"]}
{"ID": "DDI-DrugBank.d702.s2.p2", "TEXT1": "However, the co   administration of SPIRIVA with other @DRUG$   containing drugs (e.g., @DRUG$) has not been studied and is therefore not recommended.", "LBL": "0", "DRUGA": ["anticholinergic", "group", "55-69"], "DRUGB": ["ipratropium", "drug", "97-107"]}
{"ID": "DDI-DrugBank.d642.s0.p0", "TEXT1": "Prothrombin time or other suitable anticoagulation test should be monitored if @DRUG$ is administered with @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["tigecycline", "drug", "79-89"], "DRUGB": ["warfarin", "drug", "112-119"]}
{"ID": "DDI-DrugBank.d642.s1.p0", "TEXT1": "Concurrent use of @DRUG$ with oral @DRUG$ may render oral contraceptives less effective.", "LBL": "DDI-effect", "DRUGA": ["antibacterial drugs", "group", "18-36"], "DRUGB": ["contraceptives", "group", "48-61"]}
{"ID": "DDI-DrugBank.d642.s1.p1", "TEXT1": "Concurrent use of @DRUG$ with oral contraceptives may render oral @DRUG$ less effective.", "LBL": "0", "DRUGA": ["antibacterial drugs", "group", "18-36"], "DRUGB": ["contraceptives", "group", "79-92"]}
{"ID": "DDI-DrugBank.d642.s1.p2", "TEXT1": "Concurrent use of antibacterial drugs with oral @DRUG$ may render oral @DRUG$ less effective.", "LBL": "0", "DRUGA": ["contraceptives", "group", "48-61"], "DRUGB": ["contraceptives", "group", "79-92"]}
{"ID": "DDI-DrugBank.d615.s0.p0", "TEXT1": "@DRUG$ may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["central nervous system depressants", "group", "49-82"]}
{"ID": "DDI-DrugBank.d615.s0.p1", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["alcohol", "drug", "94-100"]}
{"ID": "DDI-DrugBank.d615.s0.p2", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p3", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p4", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p5", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p6", "TEXT1": "@DRUG$ may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p7", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["alcohol", "drug", "94-100"]}
{"ID": "DDI-DrugBank.d615.s0.p8", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p9", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p10", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p11", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p12", "TEXT1": "Triprolidine may enhance the sedative effects of @DRUG$ including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p13", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, @DRUG$, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p14", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p15", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, @DRUG$, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p16", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p17", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including @DRUG$, barbiturates, hypnotics, narcotic analgesics, sedatives, and @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p18", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, @DRUG$, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p19", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, @DRUG$, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p20", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, @DRUG$, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p21", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, @DRUG$, hypnotics, narcotic analgesics, sedatives, and @DRUG$.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p22", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, @DRUG$, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p23", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, @DRUG$, and tranquillisers.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p24", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, @DRUG$, narcotic analgesics, sedatives, and @DRUG$.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p25", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, @DRUG$, and tranquillisers.", "LBL": "0", "DRUGA": ["narcotic analgesics", "group", "128-146"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p26", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, @DRUG$, sedatives, and @DRUG$.", "LBL": "0", "DRUGA": ["narcotic analgesics", "group", "128-146"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p27", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, @DRUG$, and @DRUG$.", "LBL": "0", "DRUGA": ["sedatives", "group", "149-157"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s1.p0", "TEXT1": "The effects of @DRUG$, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.", "LBL": "0", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["atropine", "drug", "46-53"]}
{"ID": "DDI-DrugBank.d615.s1.p1", "TEXT1": "The effects of @DRUG$, such as atropine and @DRUG$ may be enhanced by the concomitant administration of triprolidine.", "LBL": "0", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["tricyclic antidepressants", "group", "59-83"]}
{"ID": "DDI-DrugBank.d615.s1.p2", "TEXT1": "The effects of @DRUG$, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d615.s1.p3", "TEXT1": "The effects of anticholinergic drugs, such as @DRUG$ and @DRUG$ may be enhanced by the concomitant administration of triprolidine.", "LBL": "0", "DRUGA": ["atropine", "drug", "46-53"], "DRUGB": ["tricyclic antidepressants", "group", "59-83"]}
{"ID": "DDI-DrugBank.d615.s1.p4", "TEXT1": "The effects of anticholinergic drugs, such as @DRUG$ and tricyclic antidepressants may be enhanced by the concomitant administration of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["atropine", "drug", "46-53"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d615.s1.p5", "TEXT1": "The effects of anticholinergic drugs, such as atropine and @DRUG$ may be enhanced by the concomitant administration of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["tricyclic antidepressants", "group", "59-83"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d675.s0.p0", "TEXT1": "CYP 3A4 Inhibitors (e.g. @DRUG$ and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["Protease Inhibitors", "group", "51-69"]}
{"ID": "DDI-DrugBank.d675.s0.p1", "TEXT1": "CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["ergot alkaloid drugs", "group", "178-197"]}
{"ID": "DDI-DrugBank.d675.s0.p2", "TEXT1": "CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p3", "TEXT1": "CYP 3A4 Inhibitors (e.g. @DRUG$ and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p4", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["ergot alkaloid drugs", "group", "178-197"]}
{"ID": "DDI-DrugBank.d675.s0.p5", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p6", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and @DRUG$) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p7", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. @DRUG$ and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["ergot alkaloid drugs", "group", "178-197"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p8", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain @DRUG$ (e.g. dihydroergotamine and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["ergot alkaloid drugs", "group", "178-197"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p9", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. @DRUG$ and @DRUG$) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["dihydroergotamine", "drug", "205-221"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s2.p0", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["erythromycin", "drug", "92-103"]}
{"ID": "DDI-DrugBank.d675.s2.p1", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["troleandomycin", "drug", "106-119"]}
{"ID": "DDI-DrugBank.d675.s2.p2", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p3", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p4", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p5", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p6", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p7", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p8", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p9", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p10", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p11", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p12", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include @DRUG$ (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p13", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["troleandomycin", "drug", "106-119"]}
{"ID": "DDI-DrugBank.d675.s2.p14", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p15", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p16", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p17", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p18", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p19", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p20", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p21", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p22", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p23", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p24", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., @DRUG$, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p25", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p26", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p27", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p28", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p29", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p30", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p31", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p32", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p33", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p34", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p35", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, @DRUG$, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p36", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p37", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p38", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p39", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p40", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p41", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p42", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p43", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p44", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p45", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, @DRUG$), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p46", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$@DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p47", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p48", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p49", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p50", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p51", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p52", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p53", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p54", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p55", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p56", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d739.s8.p1", "TEXT1": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as @DRUG$ or rifampin, are co-administered with @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["phenobarbital", "drug", "112-124"], "DRUGB": ["montelukast", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d675.s2.p58", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p59", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p60", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p61", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p62", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or @DRUG$ (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p63", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p64", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p65", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p66", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p67", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p68", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p69", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., @DRUG$, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p70", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p71", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p72", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p73", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p74", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p75", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, @DRUG$, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p76", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p77", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p78", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p79", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p80", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, @DRUG$, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p81", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or @DRUG$ (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p82", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p83", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p84", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, @DRUG$) or azole antifungals (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p85", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., @DRUG$, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p86", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p87", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or @DRUG$ (e.g., ketoconazole, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p88", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, @DRUG$, voriconazole).", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "270-281"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p89", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., @DRUG$, itraconazole, @DRUG$).", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "270-281"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p90", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, @DRUG$, @DRUG$).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "284-295"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s4.p0", "TEXT1": "Less potent inhibitors include @DRUG$, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["nefazodone", "drug", "43-52"]}
{"ID": "DDI-DrugBank.d675.s4.p1", "TEXT1": "Less potent inhibitors include @DRUG$, nefazodone, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluconazole", "drug", "55-65"]}
{"ID": "DDI-DrugBank.d675.s4.p2", "TEXT1": "Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p3", "TEXT1": "Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
{"ID": "DDI-DrugBank.d675.s4.p4", "TEXT1": "Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["zileuton", "drug", "111-118"]}
{"ID": "DDI-DrugBank.d675.s4.p5", "TEXT1": "Less potent inhibitors include @DRUG$, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and @DRUG$.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["clotrimazole", "drug", "125-136"]}
{"ID": "DDI-DrugBank.d675.s4.p6", "TEXT1": "Less potent inhibitors include saquinavir, @DRUG$, @DRUG$, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluconazole", "drug", "55-65"]}
{"ID": "DDI-DrugBank.d675.s4.p7", "TEXT1": "Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p8", "TEXT1": "Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
{"ID": "DDI-DrugBank.d675.s4.p9", "TEXT1": "Less potent inhibitors include saquinavir, @DRUG$, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, @DRUG$, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["zileuton", "drug", "111-118"]}
{"ID": "DDI-DrugBank.d699.s0.p0", "TEXT1": "@DRUG$ can interact with @DRUG$, antichlolinergic, TCA, MAOIs, and alcohol.", "LBL": "DDI-int", "DRUGA": ["Mequitazine", "drug", "0-10"], "DRUGB": ["CNS depressant", "group", "30-43"]}
{"ID": "DDI-DrugBank.d675.s4.p11", "TEXT1": "Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, @DRUG$, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "55-65"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p12", "TEXT1": "Less potent inhibitors include saquinavir, nefazodone, @DRUG$, grapefruit juice, fluoxetine, @DRUG$, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "55-65"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
